Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dyne Therapeutics Inc DYN

Healthcare Biotechnology
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is... see more

Recent & Breaking News (NDAQ:DYN)

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

GlobeNewswire July 12, 2022

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire July 5, 2022

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

GlobeNewswire June 3, 2022

Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

GlobeNewswire May 16, 2022

Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 2, 2022

selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform

Accesswire March 17, 2022

Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

GlobeNewswire March 10, 2022

Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

GlobeNewswire March 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Newsfile February 2, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

PR Newswire January 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

Newsfile January 25, 2022

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

GlobeNewswire January 18, 2022

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

GlobeNewswire December 2, 2021

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 4, 2021

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

GlobeNewswire October 13, 2021

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

GlobeNewswire October 1, 2021

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

GlobeNewswire September 28, 2021

Dyne Therapeutics to Present at Chardan's Virtual 5th Annual Genetic Medicines Conference

GlobeNewswire September 27, 2021

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

GlobeNewswire September 20, 2021